Cart
sales@molnova.com
hnps-PLA Inhibitor
CAS No. 185298-58-2
hnps-PLA Inhibitor( hnps-PLA Inhibitor | MDK-8582 | MDK 8582 )
Catalog No. M17396 CAS No. 185298-58-2
Hnps-PLA Inhibitor is an inhibitor of human nonpancreatic secretory Phospholipase A (hnps-PLA).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 132 | In Stock |
|
| 2MG | 70 | In Stock |
|
| 5MG | 116 | In Stock |
|
| 10MG | 202 | In Stock |
|
| 25MG | 341 | In Stock |
|
| 50MG | 498 | In Stock |
|
| 100MG | 710 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Namehnps-PLA Inhibitor
-
NoteResearch use only, not for human use.
-
Brief DescriptionHnps-PLA Inhibitor is an inhibitor of human nonpancreatic secretory Phospholipase A (hnps-PLA).
-
DescriptionMDK-8582, also known as Hnps-PLA Inhibitor, is an nhibitor of human nonpancreatic secretory Phospholipase A (hnps-PLA). The best one inhibited hnps-PLA(2) and LTA(4)H-h with IC(50) values of 9.2 ± 0.5 μM and 2.4 ± 1.4 μM, respectively.
-
In Vitro——
-
In Vivo——
-
Synonymshnps-PLA Inhibitor | MDK-8582 | MDK 8582
-
PathwayAngiogenesis
-
TargetFGFR
-
RecptorLTA(4)H-h| hnsPLA2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number185298-58-2
-
Formula Weight379.42
-
Molecular FormulaC21H21N3O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(N)C(=O)c1c(CC)n(Cc2ccccc2)c2c1c(OCC(=O)N)ccc2
-
Chemical Name2-(4-(2-Amino-2-oxoethoxy)-1-benzyl-2-ethyl-1H-indol-3-yl)-2-oxoacetamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Meng H, Liu Y, Zhai Y, Lai L. Optimization of 5-hydroxytryptamines as dual function inhibitors targeting phospholipase A2 and leukotriene A4 hydrolase. Eur J Med Chem. 2013 Jan;59:160-7
molnova catalog
related products
-
ML348
ML348 is a selective and reversible lysophospholipase 1 (LYPLA1) inhibitor (IC50 = 210 nM).
-
Vofatamab
Vofatamab (B-701) is a fully human monoclonal antibody targeting FGFR3. Vofatamab has potential anticancer and antitumor activity and is often used in combination with other compounds to treat cancer.
-
Bemarituzumab
Bemarituzumab is a novel humanized IgG1 monoclonal antibody targeting FGFR2b. Bemarituzumab prevents FGFR2b from binding to FGF and activation. Potential applications of Bemarituzumab in cancer research.
